Regen Biopharma Stock Net Income
| RGBP Stock | USD 0.01 0.0006 7.89% |
As of the 28th of January, Regen BioPharma holds the Risk Adjusted Performance of (0.02), coefficient of variation of (2,837), and Variance of 133.77. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Regen BioPharma, as well as the relationship between them.
Analyzing historical trends in various income statement and balance sheet accounts from Regen BioPharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Regen BioPharma's valuation are summarized below:Regen BioPharma does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Regen |
Regen BioPharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Regen BioPharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Regen BioPharma.
| 10/30/2025 |
| 01/28/2026 |
If you would invest 0.00 in Regen BioPharma on October 30, 2025 and sell it all today you would earn a total of 0.00 from holding Regen BioPharma or generate 0.0% return on investment in Regen BioPharma over 90 days. Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States More
Regen BioPharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Regen BioPharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Regen BioPharma upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 63.57 | |||
| Value At Risk | (17.00) | |||
| Potential Upside | 20.0 |
Regen BioPharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regen BioPharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Regen BioPharma's standard deviation. In reality, there are many statistical measures that can use Regen BioPharma historical prices to predict the future Regen BioPharma's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (1.51) | |||
| Treynor Ratio | (0.34) |
Regen BioPharma January 28, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.33) | |||
| Mean Deviation | 8.78 | |||
| Coefficient Of Variation | (2,837) | |||
| Standard Deviation | 11.57 | |||
| Variance | 133.77 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (1.51) | |||
| Treynor Ratio | (0.34) | |||
| Maximum Drawdown | 63.57 | |||
| Value At Risk | (17.00) | |||
| Potential Upside | 20.0 | |||
| Skewness | 0.7637 | |||
| Kurtosis | 1.36 |
Regen BioPharma Backtested Returns
Regen BioPharma maintains Sharpe Ratio (i.e., Efficiency) of -0.0191, which implies the firm had a -0.0191 % return per unit of risk over the last 3 months. Regen BioPharma exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Regen BioPharma's Coefficient Of Variation of (2,837), variance of 133.77, and Risk Adjusted Performance of (0.02) to confirm the risk estimate we provide. The company holds a Beta of 1.21, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Regen BioPharma will likely underperform. At this point, Regen BioPharma has a negative expected return of -0.23%. Please make sure to check Regen BioPharma's value at risk, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Regen BioPharma performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.29 |
Poor predictability
Regen BioPharma has poor predictability. Overlapping area represents the amount of predictability between Regen BioPharma time series from 30th of October 2025 to 14th of December 2025 and 14th of December 2025 to 28th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Regen BioPharma price movement. The serial correlation of 0.29 indicates that nearly 29.0% of current Regen BioPharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.29 | |
| Spearman Rank Test | 0.56 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Regen BioPharma reported net income of 2.44 M. This is 99.28% lower than that of the Healthcare sector and 96.51% lower than that of the Biotechnology industry. The net income for all United States stocks is 99.57% higher than that of the company.
Regen Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Regen BioPharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Regen BioPharma could also be used in its relative valuation, which is a method of valuing Regen BioPharma by comparing valuation metrics of similar companies.Regen BioPharma is currently under evaluation in net income category among its peers.
Regen Fundamentals
| Return On Asset | -0.76 | |||
| Profit Margin | 6.09 % | |||
| Operating Margin | (2.96) % | |||
| Current Valuation | 22.4 M | |||
| Shares Outstanding | 5.05 B | |||
| Shares Owned By Insiders | 0.06 % | |||
| Price To Sales | 89.73 X | |||
| Revenue | 235.52 K | |||
| Gross Profit | 235.52 K | |||
| EBITDA | 2.44 M | |||
| Net Income | 2.44 M | |||
| Cash And Equivalents | 110.99 K | |||
| Total Debt | 1.58 M | |||
| Debt To Equity | 1.25 % | |||
| Current Ratio | 0.05 X | |||
| Book Value Per Share | (0) X | |||
| Cash Flow From Operations | (606.92 K) | |||
| Beta | 3.36 | |||
| Market Capitalization | 10.1 M | |||
| Total Asset | 559 K | |||
| Retained Earnings | (17.78 M) | |||
| Working Capital | (478 K) | |||
| Current Asset | 171 K | |||
| Current Liabilities | 649 K | |||
| Z Score | -26.6 | |||
| Net Asset | 559 K |
About Regen BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Regen BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regen BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regen BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Regen BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regen BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regen BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving against Regen Pink Sheet
| 0.69 | REGN | Regeneron Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.68 | EC | Ecopetrol SA ADR | PairCorr |
| 0.65 | VRTX | Vertex Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.63 | PHJMF | PT Hanjaya Mandala | PairCorr |
| 0.6 | PTAIY | Astra International Tbk | PairCorr |
The ability to find closely correlated positions to Regen BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regen BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regen BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regen BioPharma to buy it.
The correlation of Regen BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regen BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regen BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regen BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Regen Pink Sheet Analysis
When running Regen BioPharma's price analysis, check to measure Regen BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regen BioPharma is operating at the current time. Most of Regen BioPharma's value examination focuses on studying past and present price action to predict the probability of Regen BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regen BioPharma's price. Additionally, you may evaluate how the addition of Regen BioPharma to your portfolios can decrease your overall portfolio volatility.